In this segment from Thursday's Market Checkup, Motley Fool health care analysts David Williamson and Michael Douglass take a look at Catamaran (NASDAQ:CTRX) following its earnings, and discuss two reasons the pharmacy benefits management company could be set to outperform in the coming year.
First, Catamaran isn't at risk of losing any big clients, with cornerstone customer Cigna firmly in place for a decade. That means investors should be able to count on more additions than subtractions. Secondly, Gilead's (NASDAQ:GILD) blockbuster hepatitis C drug Sovaldi, despite its massive price tag, could actually be a tailwind for the company as its specialty pharmacy unit Briova is poised to increase revenue in a big way this year. Demand for Sovaldi should increase Briova's reach into new areas and gain new customers.
Catamaran's positive spin on Sovaldi and solid book of business are great reasons this stock should definitely be on investors' radars.
Will this stock be your next multibagger?
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.
David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Catamaran and Gilead Sciences. The Motley Fool owns shares of Catamaran and Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.